FR2596990B1 - Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien - Google Patents

Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien

Info

Publication number
FR2596990B1
FR2596990B1 FR878705252A FR8705252A FR2596990B1 FR 2596990 B1 FR2596990 B1 FR 2596990B1 FR 878705252 A FR878705252 A FR 878705252A FR 8705252 A FR8705252 A FR 8705252A FR 2596990 B1 FR2596990 B1 FR 2596990B1
Authority
FR
France
Prior art keywords
adjuvant
bacterial
lipid emulsion
immunological
immunological adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR878705252A
Other languages
English (en)
Other versions
FR2596990A1 (fr
Inventor
John L Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2596990A1 publication Critical patent/FR2596990A1/fr
Application granted granted Critical
Publication of FR2596990B1 publication Critical patent/FR2596990B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR878705252A 1986-04-15 1987-04-14 Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien Expired - Lifetime FR2596990B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant

Publications (2)

Publication Number Publication Date
FR2596990A1 FR2596990A1 (fr) 1987-10-16
FR2596990B1 true FR2596990B1 (fr) 1990-12-07

Family

ID=25312542

Family Applications (2)

Application Number Title Priority Date Filing Date
FR878705252A Expired - Lifetime FR2596990B1 (fr) 1986-04-15 1987-04-14 Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien
FR878705271A Expired - Lifetime FR2598622B1 (fr) 1986-04-15 1987-04-14 Adjuvants immunologiques pour vaccins polysaccharidiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR878705271A Expired - Lifetime FR2598622B1 (fr) 1986-04-15 1987-04-14 Adjuvants immunologiques pour vaccins polysaccharidiques

Country Status (9)

Country Link
US (1) US4806352A (fr)
JP (1) JPS6310736A (fr)
AU (1) AU574014B2 (fr)
CA (1) CA1300503C (fr)
DE (1) DE3712767A1 (fr)
ES (1) ES2005166A6 (fr)
FR (2) FR2596990B1 (fr)
GB (1) GB2189141B (fr)
IT (1) IT1205819B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
CA1267087A (fr) * 1985-02-14 1990-03-27 Nicolaas Visser Immunogene synthetique
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
EP0324455A3 (fr) * 1988-01-15 1991-03-27 Hans O. Ribi Nouvel adjuvant immunologique polymerique
JPH04501663A (ja) * 1988-09-23 1992-03-26 ユニバーシティ・オブ・サザン・カリフォルニア 黒色腫用免疫療法ワクチン
FI902821A0 (fi) * 1989-06-12 1990-06-06 Res Found Mental Hygiene Foerminskning av infektionsspridning medelst blodbehandlingsapparatur.
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU662146B2 (en) * 1991-03-19 1995-08-24 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
DE69229779T2 (de) * 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
DE69433013T2 (de) * 1993-05-27 2004-06-03 Entremed, Inc. Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
ATE386506T1 (de) * 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
WO1999040906A2 (fr) * 1998-02-11 1999-08-19 Research Triangle Pharmaceuticals Procede et composition de traitement d'etats inflammatoires
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
CN1221249C (zh) * 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
ID29270A (id) * 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
EP1860117A3 (fr) 1999-04-09 2008-09-03 Pharmacia & Upjohn Company LLC Compositions de vaccin anti-bactérien
EP1214059B1 (fr) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Compositions particulaires, a surface modifiee, de substances biologiquement actives
ATE300949T1 (de) 2000-03-17 2005-08-15 Pharmacia & Upjohn Co Llc Ssa inaktivierte salmonella impfstoffe
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
CA2407027C (fr) 2000-04-20 2011-02-15 Rtp Pharma Inc. Procede ameliore destine aux particules de medicament insolubles dans l'eau
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
CA2420597C (fr) 2000-08-31 2011-05-17 Rtp Pharma Inc. Particules broyees
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
ATE357216T1 (de) * 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
EP1594524B1 (fr) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Utilisation de composes de tryptanthrine dans la potentialisation immunologique
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
CA2571421A1 (fr) 2004-06-24 2006-01-05 Nicholas Valiante Composes utilises pour l'immunopotentialisation
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
CA2647100A1 (fr) * 2006-03-23 2007-09-27 Novartis Ag Procedes de preparation de composes contenant de l'imidazole
CA2646891A1 (fr) * 2006-03-23 2007-09-27 Novartis Ag Composes de potentialisation immunitaire
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
CN102300483B (zh) 2010-01-29 2015-08-19 株式会社御木本 装饰品用卡扣
KR102222869B1 (ko) 2010-05-14 2021-03-04 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
WO2012010291A1 (fr) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Méthodes et compositions de diagnostic et de traitement d'une maladie métabolique
WO2012010290A1 (fr) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Méthodes et compositions de diagnostic et de traitement d'une maladie métabolique
EP2462950A1 (fr) 2010-12-08 2012-06-13 Neovacs Vaccin fortement inactivé mais immunogène hautement stable et son procédé de fabrication
AU2011340477A1 (en) 2010-12-08 2013-06-20 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2508197A1 (fr) 2011-04-07 2012-10-10 Neovacs Procédés de traitement de conditions associées à IFN alpha
EP2694094B1 (fr) 2011-04-07 2017-08-16 Neovacs MÉTHODE DE TRAITEMENT D'ÉTATS LIÉS À L'IFNalpha
EP2763698B1 (fr) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Compositions liposomales comprenant un adjuvant qui active ou accroît l'activité de tlr2 et utilisations associées
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
PL2877206T3 (pl) 2012-07-27 2020-12-14 Baxalta GmbH Kompozycje zawierające chimeryczne cząsteczki ospa i sposoby ich zastosowania
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
CA2963437A1 (fr) 2014-10-15 2016-04-21 Xenothera Composition presentant une immunogenicite reduite
WO2019236469A1 (fr) 2018-06-04 2019-12-12 Apros Therapeutics, Inc. Conjugués peptidiques de tlr7
KR20210027381A (ko) 2018-07-02 2021-03-10 아유비스 리서치, 인코포레이티드 신규 면역조절 소분자
EP3922255A1 (fr) 2020-06-10 2021-12-15 Prokarium Limited Thérapie du cancer
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (fr) 2021-07-28 2023-02-01 Prokarium Limited Thérapie du cancer avec bacteries vivantes attenuees
EP4399219A1 (fr) 2021-09-07 2024-07-17 Université de Tours Protéine de fusion de coronavirus
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (fr) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (fr) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Endotoxine detoxifiee raffinee
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
AU574014B2 (en) 1988-06-23
FR2598622B1 (fr) 1990-05-11
GB2189141B (en) 1990-07-25
ES2005166A6 (es) 1989-03-01
DE3712767C2 (fr) 1991-06-27
JPS6310736A (ja) 1988-01-18
IT1205819B (it) 1989-03-31
CA1300503C (fr) 1992-05-12
AU7156687A (en) 1987-10-22
GB8709023D0 (en) 1987-05-20
DE3712767A1 (de) 1987-10-22
GB2189141A (en) 1987-10-21
FR2596990A1 (fr) 1987-10-16
JPH041728B2 (fr) 1992-01-14
US4806352A (en) 1989-02-21
IT8747855A0 (it) 1987-04-15
FR2598622A1 (fr) 1987-11-20

Similar Documents

Publication Publication Date Title
FR2596990B1 (fr) Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien
IT8968041A0 (it) Giunto cardanico a rapporto di velocita'costante
DE68928739D1 (de) Detecteur d'humidite
FR2591674B1 (fr) Dispositif de reglage des jeux radiaux entre rotor et stator d'un compresseur
IT1217948B (it) Giunto a velocita' costante
FR2609638B1 (fr) Plancher d'entrainement
AU7609387A (en) Chagas' disease antigen
IT9020734A0 (it) dispositivo d'aspirazione
FR2523447B1 (fr) Preparation therapeutiques entimycotiques a base de creme et d'onguent
FR2593492B1 (fr) Rembourrage d'oreiller
BR1100939A (pt) Conjugado veìculo-droga e conjugado proteìna-droga
TR22839A (tr) Suebstituee edilmis belirli 3-(suebstituee oksi)-2-benzolysikloheksk 2-enon'lar
DK482488A (da) 3'-demethoxyepipodophyllotoxinglucosidderivater
FR2594057B3 (fr) Dispositif d'encochage
FR2605435B3 (fr) Panneau d'affichage
FR2634428B1 (fr) Regulateur d'embrayage
FR2616054B1 (fr) Meuble pliant pourvu d'un pietement en " x "
KR880013319U (ko) 브이씨알의 클러치장치
IT1204974B (it) Tavola d'appoggio in particolare per copiatrici
KR890005249U (ko) 벤티레이타 (Ventilatort) 의 샤후트 (Shaft) 장치
KR910003277U (ko) 브이 씨 알의 슬랜트 베이스 조립체
RO93443A2 (fr) Emollient textile en base d'esteramides
KR880007682U (ko) 시머기의 클러치장치
FR2576214B1 (fr) Compositions pharmaceutiques a base de diltiazem et d'un antihypertenseur
IT8819124V0 (it) Footing speed (velocita' di andatura)